Avoiding barriers to PET radioligand development: Cellular assays of brain efflux transporters

Journal of Nuclear Medicine

Volumn 52, Issue 3, 2011, Pages 338-340

  Hall, Matthew D ^a   Pike, Victor W ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; BREAST CANCER RESISTANCE PROTEIN; EFFLUX TRANSPORTER; FLUMAZENIL; GLYCOPROTEIN P; LOPERAMIDE; MULTIDRUG RESISTANCE PROTEIN 1; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N DESMETHYL LOPERAMIDE C 11; PRAZOSIN; RADIOLIGAND; TRACER; UNCLASSIFIED DRUG; VERAPAMIL; VERAPAMIL C 11;

BLOOD BRAIN BARRIER; CELL ASSAY; CELL LINE; GENETIC TRANSFECTION; HUMAN; MOLECULAR IMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SPECIES DIFFERENCE; TRANSPORT KINETICS;

ATP-BINDING CASSETTE TRANSPORTERS; BIOLOGICAL TRANSPORT, ACTIVE; BLOOD-BRAIN BARRIER; CELL LINE; HUMANS; KIDNEY; NEOPLASM PROTEINS; P-GLYCOPROTEIN; RADIOPHARMACEUTICALS;

EID: 79952777361     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.110.081125     Document Type: Review

References (22)

1. Pike VW. Positron-emitting radioligands for studies in vivo: probes for human psychopharmacology. J Psychopharmacol. 1993;7:139-158. (Pubitemid 23199541)
2. Laruelle M, Slifstein M, Huang Y. Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography. Mol Imaging Biol. 2003;5:363-375. (Pubitemid 37489827)
3. Patel S, Gibson R. In vivo site-directed radio-tracers: a mini-review. Nucl Med Biol. 2008;35:805-815.
4. Waterhouse RN. Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. Mol Imaging Biol. 2003;5:376-389. (Pubitemid 37489828)
5. Pike VW. PET Radiotracers: crossing the blood-brain barrier and surviving metabolism. Trends Pharmacol Sci. 2009;30:431-440.
6. Hitchcock SA. Blood-brain barrier permeability considerations for CNS-targeted compound library design. Curr Opin Chem Biol. 2008;12:318-323.
7. Elsinga PH, Hendrikse NH, Bart J, Vaalburg W, van Waarde A. PET studies on P-glycoprotein function in the blood-brain barrier: how it affects uptake and binding of drugs within the CNS. Curr Pharm Des. 2004;10:1493-1503. (Pubitemid 38559762)
8. Ishiwata K, Kawamura K, Yanai K, Hendrikse NH. In vivo evaluation of P-glycoprotein modulation of 8 PET radioligands used clinically. J Nucl Med. 2007;48:81-87.
9. Palmer AM. The role of the blood-CNS barrier in CNS disorders and their treatment. Neurobiol Dis. 2010;37:3-12.
10. Loscher W, Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx. 2005;2:86-98. (Pubitemid 40128029)
11. Raub TJ. P-glycoprotein recognition of substrates and circumvention through rational drug design. Mol Pharmacol. 2006;3:3-25. (Pubitemid 43331747)
12. Elsinga PH, Hendrikse NH, Bart J, van Waarde A, Vaalburg W. Positron emission tomography studies on binding of central nervous system drugs and P-glycoprotein function in the rodent brain. Mol Imaging Biol. 2005;7:37-44. (Pubitemid 41348874)
13. 18F]MPPF in rats. Eur J Pharmacol. 2000;407:273-280.
14. 11C](2)RWAY. Synapse. 2007;61:96-105.
15. 11C]CUMI-101, an agonist radioligand for serotonin 5-HT1A receptors, also binds to brain alpha1-adrenoceptors in rodents and monkeys. Neuroimage. 2010;52 (suppl 1):S56-S57.
16. Syvänen S, Lindhe O, Palner M, et al. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab Dispos. 2009;37:635-643.
17. 11C](-)RWAY. Synapse. 2006;60:510-520.
18. Tournier N, Valette H, Peyronneau M-A, et al. Transport of selected PET radiotracers by human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2): an in vitro screening. J Nucl Med. 2011;52:415-423.
19. Zoghbi SS, Liow J-S, Yasuno F, et al. 11C-loperamide and its N-desmethyl radiometabolite are avid substrates for brain P-glycoprotein efflux. J Nucl Med. 2008;49:649-656. (Pubitemid 351520614)
20. 11C]verapamil transfer at the human blood-brain barrier for evaluation of P-glycoprotein function. J Nucl Med. 2006;47:1531-1537.
21. Kreisl WC, Liow JS, Kimura N, et al. P-glycoprotein at the blood-brain barrier in humans can be quantified with the substrate radiotracer [11C] N-desmethyl-loperamide. J Nucl Med. 2010;51:559-566.
22. Kannan P, John C, Zoghbi SS, et al. Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin Pharmacol Ther. 2009;86:368-377.